구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Second generation CAR-T cells (Second generation CAR-T cells) Wuhan Sian Medical Technology Co.,…·Acute Lymphoblastic Leukemia 46 trials |
|---|---|
Overview Program | Second generation CAR-T cells |
Overview Company | Wuhan Sian Medical Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral expression vector and removed epitope tags used to discriminate between CAR and |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Toxicology CRS | Reported |
Clinical Safety signal | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Second generation CAR-T cells (Second generation CAR-T cells) Wuhan Sian Medical Technology Co.,…·Acute Lymphoblastic Leukemia 46 trials |
|---|---|
Overview Program | Second generation CAR-T cells |
Overview Company | Wuhan Sian Medical Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral expression vector and removed epitope tags used to discriminate between CAR and |
MoA Mechanism | targeting a human tumor-specific antigen |
MoA Biomarker | Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Toxicology CRS | Reported |
Clinical Safety signal | Advances in CAR optimization strategies based on CD28.. Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and c… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교